Pegfilgrastim biosimilar - Jiangsu Hengrui Medicine Co.Alternative Names: HHPG-19K; Pegylated rhG-CSF - Jiangsu Hengrui
Latest Information Update: 11 Sep 2015
Price : $50
At a glance
- Originator Jiangsu Hengrui Medicine Co.
- Class Chemoprotectants; Granulocyte colony-stimulating factors; Polyethylene glycols; Recombinant proteins
- Mechanism of Action Granulocyte stimulants; Haematopoiesis stimulants
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase III Neutropenia
Most Recent Events
- 15 Mar 2016 Biomarkers information updated
- 06 May 2015 Phase-III development is ongoing in China
- 01 Jan 2013 Jiangsu Hengrui Medicine Co. completes a phase III trial in Neutropenia (chemotherapy-induced, prevention) in China (NCT01611051)